Name | 2-(2,6-diaminopurin-9-yl)ethoxymethylphosphonic acid |
---|---|
Synonyms |
{[2-(2,6-diamino-9h-purin-9-yl)ethoxy]methyl}phosphonic acid
N-(2-Phosphonomethoxyethyl)-2,6-diaminopurine 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine 9-(2-phosphonomethoxyethyl)-2,6-diaminopurine 2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine 5-(3-Hydroxy-2-phosphonomethoxypropyladenine) PME-DAP Phosphonic acid,((2-(2,6-diamino-9H-purin-9-yl)ethoxy)methyl) PMEDAP |
Description | PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication. PMEDAP has anti-murine cytomegalovirus (MCMV) activity. PMEDAP is a very potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality[1][2]. |
---|---|
Related Catalog | |
In Vivo | PMEDAP (0.25-5 mg/kg; IP; daily; starting on the day of MSV-infected and continuing for an additional four days) causes a dose-dependent suppression of tumor formation and mortality in newborn mice inoculated with MSV[1]. Animal Model: Three-week-old male NMRI mice[1] Dosage: 0.25 mg/kg, 1 mg/kg, 5 mg/kg Administration: IP; daily; starting on the day of infection and continuing for an additional four days Result: Effected a significant delay in tumor appearance and an enhancement of the survival rate of tumor-bearing mice. |
References |
Density | 2.03g/cm3 |
---|---|
Boiling Point | 748.7ºC at 760mmHg |
Molecular Formula | C8H13N6O4P |
Molecular Weight | 288.20 |
Flash Point | 406.6ºC |
Exact Mass | 288.07400 |
PSA | 172.94000 |
Vapour Pressure | 1.51E-23mmHg at 25°C |
Index of Refraction | 1.826 |
Hazard Codes | Xi |
---|